VEGFA and cholangiocarcinoma: There have been various other drugs like VEGF inhibitors (axitinib, lenvatinib, ramucirumab, and regorafenib) and PARP inhibitors (olaparib, rucaparib) in early-phase clinical trials being tested in combination with immunotherapy to improve outcomes in patients with advanced cholangiocarcinoma.